GSK:NYSE
GSK plc
$47.02
arrow_upward
+0.90%(+0.42) 1D
$46.39
arrow_downward
-1.34% (-0.63)todayPre-market
Closed: Oct 7, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$46.92
High
$47.40
Low
$46.69
Mkt. cap
95.26B
Avg. vol.
3.41M
Volume
41.68K
Dividend
3.86%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.01
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.13
Beta
0.25
Shares outstanding
2.02B
No. of employees
67K
Open
$46.92
High
$47.40
Low
$46.69
Mkt. cap
95.26B
Avg. vol.
3.41M
Volume
41.68K
Dividend
3.86%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
15.01
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.13
Beta
0.25
Shares outstanding
2.02B
No. of employees
67K
News stories
From web sources and news partners
Analytics Insight
·
1 hour ago
AstraZeneca vs GSK: Comparing Two UK Stocks in AI-Driven Healthcare
JournalArta
·
8 hours ago
Momentum Weakens, GSK Stock Gains 1.42%: What to Know
AD HOC NEWS
·
22 hours ago
GSK stock adds a liver candidate to its pipeline
Traders Union
·
1 day ago
GSK shares technical analysis: Resistance test at GBX1,769 limits rebound
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com